IMPDH2 and cancer: Furthermore, stepwise acquisition of doxorubicin resistance resulted in increased levels of IMPDH2 and its endpoint metabolite GTP, which paradoxically created a novel vulnerability in the cancer cells, rendering them exquisitely sensitive to IMPDH2 depletion or inhibition, both in vitro and in vivo.